Abstract: Hematopoietic stem cell transplantation (HSCT) is the only effective curative therapy for patients with certain hematological diseases. Haploidentical HSCT has been practiced worldwide for approximately twenty years. Significant improvements on this therapy were made in China within the past decade, with the novel non- in-vitro , T-cell-depleted haploidentical HSCT system. This review de -scribes the current situation and provides a prospective overview of these novel HSCT systems in China.